Lexicon Pharmaceuticals (Nasdaq: LXRX) $1.97. Today announced it has obtained positive results from a recently completed Phase 2 study of LX4211 in patients type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load. LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating statistically significant benefits in the primary and multiple secondary efficacy endpoints.
What They Do: LX4211 was developed at Lexicon as a potent inhibitor of the sodium glucose cotransporter 2 (SGLT2), a transporter responsible for the majority of glucose reabsorption by the kidneys.
Echo Therapeutics (OTCBB: ECTE) $1.69. A company developing the needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude SkinPrep System for transdermal drug delivery, announced yesterday that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Wednesday, January 20, 2010 at 9:42 AM ET and Friday January 22, 2010 at 10:24 AM ET. Dr. Mooney also will be a regular on-air guest on American Scene twice weekly and will be interviewed by host Steve Crowley regarding relevant corporate events, news releases and updates.
What They Do: Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.
Gilead Sciences (Nasdaq: GILD) $46.28. Announced Tuesday after market close that its fourth quarter and year end 2009 financial results will be released on Tuesday, January 26, 2010, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2009 and provide a general business update and financial guidance for 2010. The conference call will be accessible via the internet from the company’s website.
What They Do: Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
Teva Pharmaceutical Industries (Nasdaq: TEVA) %58.17. Announced yesterday that it will be donating over $7 million in medicine to benefit earthquake victims in Haiti. Teva is working with several of its Non-Governmental Organization (NGO) partners to ensure these drugs are delivered to Haiti without delay.
“As a company, Teva was devastated to hear about the earthquake and our hearts and thoughts go out to the country of Haiti,” said Shlomo Yanai, Teva’s President and Chief Executive Officer. “Working with our partners, we are providing essential medical products to assist in the relief efforts.”
What They Do: Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has been compensated three thousand five hundred dollars by a third party Green Horseshoe for its services with regards to Echo Therapeutics. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
